A distinct strategy to generate high-affinity peptide binders to receptor tyrosine kinases

Protein Engineering, Design and Selection

Volumn 18, Issue 9, 2005, Pages 417-424

  Shrivastava, A ^a   Von Wronski, M A ^a   Sato, A K ^b   Dransfield, D T ^b   Sexton, D ^b   Bogdan, N ^a   Pillai, R ^a   Nanjappan, P ^a   Song, B ^a   Marinelli, E ^a   DeOliveira, D ^b   Luneau, C ^b   Devlin, M ^b   Muruganandam, A ^b   Abujoub, A ^b   Connelly, G ^b   Wu, Q L ^b   Conley, G ^b   Chang, Q ^b   Tweedle, M F ^a   Ladner, R C ^b   Swenson, R E ^a   Nunn, A D ^a   more..

^a Bracco Research USA   (United States)

^b Dyax Corp   (United States)

Author keywords

c MET; HAPs; Heterodimer; Peptide; VEGFR 2

Indexed keywords

BINDERS; DIMERIZATION; MONOMERS; SYNTHESIS (CHEMICAL);

C-MET; HAPS; HETERODIMER; HIGH AFFINITY PEPTIDE (HAP) BINDERS; PEPTIDES; RECEPTOR TYROSINE KINASES (RTK); VEGFR-2;

ENZYMES;

PEPTIDE; PROTEIN TYROSINE KINASE; SCATTER FACTOR RECEPTOR; VASCULOTROPIN RECEPTOR 2;

ARTICLE; BINDING AFFINITY; BINDING ASSAY; DIMERIZATION; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN FOLDING; SENSITIVITY ANALYSIS; SYNTHESIS;

DIMERIZATION; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG SYNERGISM; HUMANS; PEPTIDE LIBRARY; PEPTIDES; PROTEIN BINDING; PROTEIN INTERACTION MAPPING; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR PROTEIN-TYROSINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

EID: 24044486898     PISSN: 17410126     EISSN: None     Source Type: Journal    
DOI: 10.1093/protein/gzi049     Document Type: Article

References (42)

1. Abou-Jawde,R., Choueiri,T., Alemany,C. and Mekhail,T. (2003) Clin. Ther., 25, 2121-2137.
2. Adams,G.P. and Schier,R. (1999) J. Immunol. Methods, 231, 249-260.
3. Aina,O.H., Sroka,T.C., Chen,M.L. and Lam,K.S. (2002) Biopolymers, 66, 184-199.
4. Allen,T.M. (2002) Nat. Rev. Cancer, 2, 750-763.
5. Alon,R., Bayer,E.A. and Wilchek,M. (1990) Biochem. Biophys. Res. Commun., 170, 1236-1241.
6. Bennasroune,A., Gardin,A., Aunis,D., Cremel,G. and Hubert,P. (2004) Crit. Rev. Oncol. Hematol., 50, 23-38.
7. Bikfalvi,A., Sauzeau,C., Moukadiri,H., Maclouf,J., Busso,N., Bryckaert,M., Plouet,J. and Tobelem,G. (1991) J. Cell Physiol., 149, 50-59.
8. Bottaro,D.P., Rubin,J.S., Faletto,D.L., Chan,A.M., Kmiecik,T.E., Vande Woude,G.F. and Aaronson,S.A. (1991) Science, 251, 802-804.
9. Bratthauer,G.L. (1999) Methods Mol. Biol., 115, 203-214.
10. Burke,T.J., Loniello,K.R., Beebe,J.A. and Ervin,K.M. (2003) Comb. Chem. High Throughput Screen., 6, 183-194.
11. Connor,B. and Dragunow,M. (1998) Brain Res. Brain Res. Rev., 27, 1-39.
12. Danilkovitch-Miagkova,A. and Zbar,B. (2002) J. Clin. Invest., 109, 863-867.
13. Fairbrother,W.J., Christinger,H.W., Cochran,A.G., Fuh,G., Keenan,C.J., Quan,C., Shriver,S.K., Tom,J.Y., Wells,J.A. and Cunningham,B.C. (1998) Biochemistry, 37, 17754-17764.
14. Feng,D., Nagy,J.A., Brekken,R.A., Pettersson,A., Manseau,E,J., Pyne,K., Mulligan,R., Thorpe,P.E., Dvorak,H.F. and Dvorak,A.M. (2000) J. Histochem. Cytochem., 48, 545-555.
15. Ferrara,N., Gerber,H.P. and LeCouter,J. (2003) Nat. Med., 9, 669-676.
16. Fleming,T.J. et al. (2004) J. Mol. Recognit., 18, 94-102.
17. Folkman,J. (1971) N. Engl. J. Med., 285, 1182-1186.
18. Folkman,J. (2003) Curr. Mol. Med., 3, 643-651.
19. Hetian,L., Ping,A., Shumei,S., Xiaoying,L., Luowen,H., Jian,W., Lin,M., Meisheng,L., Junshan,Y. and Chengchao,S. (2002) J. Biol. Chem., 277, 43137-43142.
20. Hiller,Y., Gershoni,J.M., Bayer,E.A. and Wilcheck,M. (1987) Biochem. J., 248, 167-171.
21. Jiang,G. and Hunter,T. (1999) Curr. Biol., 9, R568-R571.
22. Lemmon,M.A. and Schlessinger,J. (1994) Trends Biochem. Sci., 19, 459-463.
23. Lin,P., Sankar,S., Shan,S., Dewhirst,M.W., Polverini,P.J., Quinn,T.Q. and Peters,K.G. (1998) Cell Growth Differ., 9, 49-58.
24. Malmqvist,M. (1999) Biochem. Soc. Trans., 27, 335-340.
25. Melkko,S., Scheuermann,J., Dumelin,C.E. and Neri, D. (2004) Nat. Biotechnol., 22, 568-574.
26. Mori, T. (2004) Curr. Pharm. Des., 10, 2335-2343.
27. Mourez,M., Kane,R.S., Mogridge,J., Mettalo,S., Deschatelets,P., Sellman,B.R., Whitesides,G.M. and Collier,R.J. (2001) Nat. Biotechnol., 19, 958-961.
28. Pastan,I. and Kreitman,R.J. (2002) Curr. Opin. Invest. Drugs, 3, 1089-1091.
29. Pillai,R., Marinelli,E. and Swenson,R. (2004) In Flegel,M., Fridkin,M., Gilon,C., Lebl,M. and Slaninova,J. (eds), Proceedings of the 3rd International and 28th European Peptides Symposium, in press.
30. Quinn,T.P., Peters,K.G., De Vries,C., Ferrara,N. and Williams,L.T. (1993) Proc. Natl Acad. Sci. USA, 90, 7533-7537.
31. Reff,M.E., Hariharan,K. and Braslawsky,G. (2002) Cancer Control, 9, 152-166.
32. Sadler,K. and Tam,J.P. (2002) J. Biotechnol., 90, 195-229.
33. Sato,A.K. et al. (2002) Biotech. Prog., 18, 182-192.
34. Schaffer,L. et al. (2003) Proc. Natl Acad. Sci. USA, 100, 4435-4439.
35. Schlessinger,J. (1988) Trends Biochem. Sci., 13, 443-447.
36. Schlessinger,J. (2000) Cell, 103, 211-225.
37. Szardenings,M. (2003) J. Recept. Signal Transduct. Res., 23, 307-349.
38. Terman,B.I., Carrion,M.E., Kovacs,E., Rasmussen,B.A., Eddy,R.L. and Shows,T.B. (1991) Oncogene, 6, 1677-1683.
39. Thorpe,P.E. (2004) Clin. Cancer Res., 10, 415-427.
40. Ullrich,A. and Schlessinger,J. (1990) Cell, 61, 203-212.
41. Vlahovic,G. and Crawford,J. (2003) Oncologist, 8, 531-538.
42. Zwick,E., Bange,J. and Ullrich,A. (2002) Trends Mol. Med., 8, 17-23.